Corporate insiders tend to have superior knowledge of their firms’ operating, financing, and investing activities. If they’re buying stock, it’s often worth taking a closer look.

In this report, we are going to highlight some interesting insider buying at IQVIA Holdings Inc (IQV:US). IQVIA is an American company that provides integrated information and technology-enabled healthcare services. Its goal is to create a more modern and effective healthcare system and create breakthrough solutions that transform business and patient outcomes. The company is listed on the New York Stock Exchange and currently has a market capitalization of $53.1 billion.

IQVIA Holdings Inc: Insider Buying

Our data shows that on December 22, board member John Danhakl bought 10,000 IQV shares at a price of $272.93 per share. This trade cost the insider $2.7 million and increased his holding to 24,344 shares.

High-Conviction Purchase

This trade is worth highlighting for several reasons.

Firstly, by purchasing 10,000 shares, Mr. Danhakl has increased the size of his position by 70%. This suggests he is very confident that the stock is set to move higher.

Secondly, our data shows that Mr. Danhakl has made well-timed purchases in the recent past. In December 2020, the insider picked up 63,451 shares at a price of $176.95 per share. Since then, the stock has risen to near $280.

Additionally, it’s worth noting that Mr. Danhakl – who has served on the board since 2016 – has an investment background. Currently, he is a Managing Partner at private equity firm LGP, which he joined in 1995. This means he’s likely to have a good understanding of the intrinsic value here.

Guidance Raised

IQVIA appears to have a lot of momentum at present.

For the third quarter of 2021, the company posted revenue of $3,391 million, up 21.7% year on year, and adjusted diluted earnings per share (EPS) of $2.17, up 33.1% year on year. On the back of this strong performance, the group raised its full-year 2021 guidance for revenue, adjusted EBITDA and adjusted diluted EPS.

Meanwhile, at its investor day in mid-November, the company provided a very upbeat forecast for 2022. It now expects revenue of $14.70 billion to $15.0 billion (vs estimated revenue of $13.8 billion for 2021) and adjusted EPS of $9.90 to $10.20 for 2022. It also expects higher revenue growth of 10% to 12% per year or 2022 to 2025.

Given the momentum here, we see the insider buying as a bullish indicator.